Chiome Bioscience Inc. announced that it has submitted an initial application for a Phase I clinical trial on CBA-1205 to the Pharmaceuticals and Medical Devices Agency (PMDA) on March 24, 2020. CBA-1205 is a novel afucosylated humanized antibody targeting cell surface antigen DLK-1 which expresses on several types of solid cancer, such as liver cancer and lung cancer. There has been no development targeting DLK-1 and it is the first-in-class target. Also, this trial is the first-in-human Phase I study and is scheduled to start after the PMDA's 30-day review period and the approval from the Institutional Review Board of clinical sites.